
    
      This is a multicenter, phase II neoadjuvant trial in hormone-sensitive, HER-negative, luminal
      B, premenopausal breast cancer patients stage II-IIIA.

      Patients will undergo a core-biopsy of the primary tumor, for the histological diagnosis and
      the biological characterization of the tumor.

      After confirmation of eligibility and informed consent signature, the patients will start
      neoadjuvant treatment including:

      Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed
      by the combination of Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses and
      exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). Patients
      will start LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) concomitantly to
      anthracycline-based chemotherapy, to be continued until surgery.
    
  